Company

Omios Biologics

Biotechnology Research Alameda, California, United States 4 employees

Employees: 4
Contacts: 2
Emails: 2
Phones: 1

Omios Biologics Overview

Headquarters: Alameda, California, United States
Industry: Biotechnology Research
Employees: 4
Founded: 2021
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

oncolytic vaccine oncolytic virus immunotherapy cancer vaccine Immunogenic Cell Death Innate immune response Cancer surveillance systemic delivery gene delivery

About Omios Biologics

Omios Bio is developing next-generation oncolytic virus therapy to treat solid tumors. Cancer is a complex disease that requires complex therapies. Our patented platform technology uses a novel vaccinia virus to target cancer cell mutations in cell death programs offering exceptional cancer selectivity, and maximum cancer cell destruction. Omios OV therapy overcomes limitations of current therapies by directly reaching metastases in a selective way, have an improved tolerability, no resistance, prevent relapse, and offer a durable effect. With a strong team, proven technology, and a large market opportunity, Omios is poised to revolutionize cancer treatment.

Omios Biologics Contact Details

People in AeroLeads: 3
With contact data: 2
Email contacts: 2; 66.7% coverage
Phone contacts: 1; 33.3% coverage

Omios Biologics Org Chart

Sample employees and titles

Name	Title	Location	Contact
Laurence Nore	Life Sciences Executive ★ Board Member & Angel Investor ★ Passion for Biotech ★ EVP at Iggenix		View
Bruno Larida	Pioneering Oncolytic Virus Immunotherapy to End Cancer & Improve Patient Lives	San Francisco, California, United States	Email Phone
Aldo Pourchet	Founder & CEO at Omios Biologics	San Francisco Bay Area, United States	Email